Tests omega-3 fatty acids in youth with autism spectrum disorder
Tests omega-3 supplements against a placebo in children and teens with autism.
Key facts
- Who runs it
- China Medical University Hospital
- Where
- Taichung, TaiwanSee the site
- Trial code
- Registry title
- Omega-3, Autism Spectrum Disorder (ASD)
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 15 Jul 2022
- Planned end
- 31 Jul 2026
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Omega-3
- Placebo
- Record updated
- 26 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 6-17 with autism spectrum disorder. It tests omega-3 fatty acids against placebo over 12 weeks.
- Age
- 6-17 years old at enrolment.
- Sex
- All sexes can join.
- Disease stage
- Autism spectrum disorder (DSM5), diagnosed by a child and adolescent psychiatrist.
- Earlier treatment
- No change in medicine or other therapy in the past 4 weeks. Cannot be using omega-3 supplements or probiotics now.
Main reasons for not taking part
- Other psychiatric disorders, such as schizophrenia, bipolar disorder, major depression or substance use disorder
- Physical disorders such as thyroid dysfunction, cerebral palsy or coagulation disorders
- Currently using omega-3 supplements or probiotics
- Allergy to omega-3
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- diagnosis of DSM5 ASD made by child and adolescent psychiatrist
- age 6-17 years-old at the time of enrolment
- no pharmacotherapy or non-pharmacotherapy adjustment within the past 4 weeks,
- Signed informed consent
Who cannot take part
- currently using omega-3 supplements or probiotics
- comorbid other psychiatric disorders, including schizophrenia or affective mood disorder (Bipolar and Major Depressive Disorder), or substance use disorder
- comorbid physical disorders, such as thyroid dysfunction, cerebral palsy, coagulation disorders
- allergy to omega-3
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Where in Taiwan
- China Medical UniversityTaichung, TaiwanContact: Pei-Chen Chang, MD, PHDTaking people
About the trial
What the trial wants to find out
This is a 12 week study to investigate the effects of omega-3 polyunsaturated fatty acids (PUFAs) in youth with autism spectrum disorder (ASD).
The 3 groups in the trial
- Omega-3 (EPA)Treatment being tested
EPA
Treatment: Omega-3
- PlaceboPlacebo, for comparison
Soybean Oil
- Omega-3 (DHA)Treatment being tested
DHA
Treatment: Omega-3
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Omega-3 Fatty Acids and Autism Spectrum Disorder (ASD) - A Double-blind Randomized Controlled Trial of Omega-3 Fatty Acids in Youth With ASD
- Plain-language title
- Tests omega-3 fatty acids in youth with autism spectrum disorderGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07365553, who can take part
- Record updated
- 26 January 2026